Finch Therapeutics Group Past Earnings Performance
Past criteria checks 0/6
Finch Therapeutics Group's earnings have been declining at an average annual rate of -13.5%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 108.4% per year.
Key information
-13.5%
Earnings growth rate
27.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -108.4% |
| Return on equity | -99.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Revenue & Expenses Breakdown
How Finch Therapeutics Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -14 | 20 | 0 |
| 31 Mar 24 | 0 | -16 | 22 | 0 |
| 31 Dec 23 | 0 | -75 | 27 | 0 |
| 30 Sep 23 | 0 | -99 | 33 | 0 |
| 30 Jun 23 | 0 | -137 | 37 | 0 |
| 31 Mar 23 | 1 | -152 | 36 | 0 |
| 31 Dec 22 | 1 | -115 | 36 | 0 |
| 30 Sep 22 | 2 | -107 | 32 | 0 |
| 30 Jun 22 | 13 | -76 | 28 | 0 |
| 31 Mar 22 | 15 | -69 | 26 | 0 |
| 31 Dec 21 | 19 | -58 | 21 | 0 |
| 30 Sep 21 | 20 | -52 | 23 | 0 |
| 30 Jun 21 | 10 | -52 | 20 | 0 |
| 31 Mar 21 | 9 | -45 | 16 | 0 |
| 31 Dec 20 | 8 | -39 | 14 | 0 |
| 31 Dec 19 | 10 | -21 | 7 | 0 |
Quality Earnings: FNCH is currently unprofitable.
Growing Profit Margin: FNCH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FNCH is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.
Accelerating Growth: Unable to compare FNCH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FNCH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: FNCH has a negative Return on Equity (-99.63%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 23:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Finch Therapeutics Group, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Maneka Mirchandaney | Evercore ISI |
| Vernon Bernardino | H.C. Wainwright & Co. |